Member Info for WeTookPelham

Exactly RW. Very interesting, but not unsurprising. Some different names but same rhetoric. Like you say, a good old tradition.
I couldn't even be bothered to reply to the post about the South African approval process, it was clear for everyone to see what it's aim was.

Hi Bill, can you translate/disect that for me please. By setting up the subsidiary they are more likely to list on the NASDAQ because it saves Redmile going over their threshold?

https://www.bbc.co.uk/news/health-57761343

@kashdog you posted "Looks like Clover is the preferred option for CEPI.
This link is in the CEPI newsletter of today with no mention of Scancell!"

Well basically your "thoughts" seem very badly thought out, both IMO and by others too. 2cvguys sums it up perfectly. And also it was an article about Clover, why would they mention Scancell?

"In no way does it rule out Scancell from CEPI funding."
Exactly this.
Kashdog wanting to twist the news to fit his agenda lol. Need to brush up on the de-ramping skills there me thinks :)

What's the date of that article?
Nice find btw.

For comparison/reference here are some of the roles from last October (2020):
https://twitter.com/DixonLabNotts
https://jobs.nottingham.ac.uk/Vacancy.aspx?id=31302&forced=2
https://jobs.nottingham.ac.uk/Upload/vacancies/files/31301/SCI312520.pdf
https://jobs.nottingham.ac.uk/Vacancy.aspx?id=31323&forced=2
https://jobs.nottingham.ac.uk/Upload/vacancies/files/31322/SCI312320.pdf

https://www.jobs.ac.uk/job/CHE851/mrc-impact-dtp-icase-phd-studentship

Have a feeling this is recruiting additional PhD students to the same study?

... IMO. Not seen these smaller trades for a few weeks now I think?

Also, is 282 the mm code for $28.2 billion buy out? I'm guessing it is.

@Burble - great post, Scancell should use it when promoting!

https://events.marketsandmarkets.com/4th-annual-next-gen-immuno-oncology-virtual-congress-us-edition/speakers

"WTP nice one i can see the Scancell jobs but what about the one through Yoh agency that the link takes you too."

Hi SG, yes that's what I meant, the main Antibodies expert role mentioned on that page, could it be for Scancell? I found it when I did a search for "Scancell" last 24 hours on Google.

I'm unclear, because haven't Scancell been advertising directly rather than using agencies? But maybe it is for Zakari hence no company name mentioned?

https://jobs.newscientist.com/en-gb/job/1401735002/senior-scientist-antibody-discovery/

American interest? Approx 8am east coast time?

https://www.durham.ac.uk/staff/adam-benham/

"Our work on immune molecules (the Major Histocompatibility Complex or MHC) seeks to explain how these proteins are loaded with their peptide cargo and how oxidative protein folding and ER chaperones contribute to their quality control. This has applications in understanding neoantigen presentation and in the design of cancer vaccines. In BBSRC funded work, we are working with Scancell, Notingham and Liverpool University to determine the trafficking of MHC-neoantigen complexes."

Can one of the science types explain which of Scancell's platforms this relates to? Immunobody?

Not sure if alreadsy posted:
https://www.trinitydelta.org/research-notes/covidity-programme-to-start-phase-i-in-h221/

Well the trials have rns'd so why not!

Yes, "please" no more CH presentations, RNS's and tweets will do.

...is that "lots" is happening in the background with Scancell atm, and lots a pieces seemed to moving into place.

Just in the last few days/weeks we have had:
- Covid trial announcement
- New (secret) subsidiary
- Another three science staff being recruited
- New American joint broker who specialise in M&A
- Another director buy

All this and the SP has barely moved lol, In fact I'm still astounded by the SP reaction to yesterday's news. Oh well, wasn't planning on topping up...but if you insist.

Bermuda's answer as per usual sounds very well thought out.
But yes, a shell to establish a standalone company for one of the platforms like Avidimab or Moditope perhaps?

NXC's original post and Bermuda's reply

"22/6/2021
22:41 bermudashorts: I assume the intention is at some stage to move glycan mAbs IP across to facilitate future deals? Edited to add that if the company is sitting there as an inactive shell atm in preparation for any future strategic moves then doesn't it only become price sensitive as and when they implement that strategy (whatever it may be)?

22/6/2021
22:38 nxc: I have not been on this BlackBerry for a while due to being on a crusade against the continued use of the Innova LFT so apologies if you have had a discussion on this but what is the gig with Sclp establishing Zakari Therapeutics as a separate subsidiary? The Company has deemed it not to be price sensitive"